ational Application No

، ناهج ۾ ناريء

A. CLAS	SSIFICATION OF SUBJECT MATTER		1617 Er 2004/0058/5		
IPC 7	7 A61K35/78 A61P29/00				
According	a to International Passant On the Control of the Co				
B. FIELD	g to International Patent Classification (IPC) or to both nation DS SEARCHED	al classification and IPC			
Minimum IPC 7	documentation searched (classification system followed by	classification symbols)			
110	A61K A61P	, , , , , , , , , , , , , , , , , , ,	•		
Dogimen	station searched others.				
	alation searched other than minimum documentation to the ex	tent that such documents are includ	ed in the fields searched		
Flectronic	triata hase consulted during the feet				
FPO-T	data base consulted during the International search (name	of data base and, where practical, s	earch terms used)		
1 2.0 1.	nternal, WPI Data, PAJ, BIOSIS,	EMBASE, FSTA			
1					
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT				
Category •		Of the relevant passages			
		o mo roisvam passages	Relevant to claim No.		
X	CHRUBASIK S ET AL: "TREATME	NT OF	1-6		
	RHEUMATIC PAIN WITH HERBAL M	EDICINE IN	1 0		
	PAIN DIGEST, SPRINGER NEW YO	ORK. NY. US.			
	Vol. 8, no. 4, 1998, pages 2 XP009014438	31–236,			
	ISSN: 0938-9016		1		
	page 231, column 1, paragrapi table 2	ns 2,3	1		
X	DATABASE MEDLINE 'Online!	1-6			
	US NATIONAL LIBRARY OF MEDICI BETHESDA, MD, US; 2002,				
	CHRUBASIK SIGRUN ET Al · "'Pai	n management			
1	with herbal antirheumatic dru XP002298411	gs!"			
	Database accession no. NLM120				
1	abstract abstract	}			
- (	abstract	-/	1		
X Furthe	or degree on the sales				
	er documents are listed in the continuation of box C.	X Patent family memb	ers are listed in annex.		
	egories of cited documents :	"T" later document published	after the international filing date		
Wilaide!	It defining the general state of the art which is not red to be of particular relevance		acter the international filing date in conflict with the application but principle or theory underlying the		
ming dat	cument but published on or after the international	*X* document of particular rel	evance; the claimed invention ivel or cannot be considered to		
	which may throw doubts on priority claim(s) or cited to establish the publication date of another or other special reason (as specified)	mivolve an diventive step	when the document is taken alone evance; the claimed invention		
document other me	t referring to an oral disclosure, use, exhibition or	document is combined w	involve an inventive step when the		
document	published prior to the international filing date but the priority date claimed	in the art.	being obvious to a person skilled		
le of the actual completion of the international search			*&* document member of the same patent family  Date of mailing of the international search report		
		Pale of making of the Intel	mational search report		
	September 2004	20/10/2004			
me and mail	ling address of the ISA European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer			
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.				
	Fax: (+31-70) 340-3016	Peris Antol	1, B		

ational Application No

Category of	uation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/EP2004/005875	
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
	& WIENER MEDIZINISCHE WOCHENSCHRIFT (1946) 2002, vol. 152, no. 7-8, 2002, pages 198-203, ISSN: 0043-5341		
X	US 5 629 351 A (TANEJA SUBHASH C ET AL) 13 May 1997 (1997-05-13) claim 2 column 4, lines 40-45	1-6	
(	US 2002/010168 A1 (AMMON HERMANN P T ET AL) 24 January 2002 (2002-01-24) claims 1,2	1-6	
	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 1999 (1999-09), ZHAO J ET AL: "Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent." XP002298412 Database accession no. NLM10469619 abstract: 1st sentence abstract & CARCINOGENESIS. SEP 1999, vol. 20, no. 9, September 1999 (1999-09), pages 1737-1745, ISSN: 0143-3334	1-6	
	US 4 870 061 A (SPECK ULRICH) 26 September 1989 (1989-09-26) claim 1	1-6	
	EP 0 864 580 A (HAYASHIBARA BIOCHEM LAB; CHUGOKU KAYAKU (JP)) 16 September 1998 (1998-09-16) page 4, lines 10-14	1–6	
	GB 1 015 800 A (FUJISAWA PHARMACEUTICAL CO) 5 January 1966 (1966-01-05) page 1, lines 28-31	1-6	
ISA/340 (co	tlinuation of second sheet) (January 2004)		

International Application No FC I/EP2004/005875

Continue	ion) DOCUMENTS CONSIDERED TO BE RELEVANT	rci/EP2004/005875
Calegory °	Citation of document, with indication, where appropriate, of the relevant passages	
		Relevant to claim No.
, X	TAMAI Y ET AL: "Enhanced healing of cartilaginous injuries by N-acetyl-d-glucosamine and glucuronic acid" CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 54, no. 2, 1 November 2003 (2003-11-01), pages 251-262, XP004452621 ISSN: 0144-8617 abstract page 262, column 1, paragraph 2	Relevant to claim No.  1-6

Information on patent family members

I----ational Application No

		EP2004/0058/5				
	atent document d in search report	_	Publication date		Patent family member(s)	Publication date
US	5629351	Α	13-05-1997	EP	0755940 A1	29-01-1997
US	2002010168	A1	24-01-2002	DE	19531067 A1	27-02-1997
				AT	200422 T	15-04-2001
				DE	59606784 D1	17-05-2001
				DK	854709 T3	18-06-2001
				WO	9707796 A1	06-03-1997
				EP	0854709 A1	29-07-1998
				ES	2157005 T3	01-08-2001
				JP	11511448 T	05-10-1999
				PΤ	854709 T	30-08-2001
US	4870061	Α	26-09-1989	DE	3602670 A1	30-07-1987
				CA	1288346 C	03-09-1991
				EP	0234207 A2	02-09-1987
				JP	62185017 A	13-08-1987
			·	ZA	8700074 A	25-05-1988
EP	0864580	Α	16-09-1998	JP	10251263 A	22-09-1998
				DE.	69815179 D1	10-07-2003
				DĒ	69815179 T2	19-05-2004
				EP	0864580 A2	16-09-1998
				TW	476759 B	21-02-2002
				US	5912361 A	15-06-1999
GB	1015800	Α	05-01-1966	FR	3970 M	

ternational application No.

PCT/EP2004/005875

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to formulations comprising combinations of analgesic/anti-inflammatory, immunomodulating and cartilage-reconstructing agents, in particular comprising saligenin, boswellic acid, procyanidins, N-acetyl-glucosamine and either glucuronic acid or glucuronolactone, for the treatment of rheumatoid arthritis and, more generally, of arthritis conditions.